4//SEC Filing
Kelly Michael 4
Accession 0001209191-22-056440
CIK 0001671858other
Filed
Nov 9, 7:00 PM ET
Accepted
Nov 10, 6:00 PM ET
Size
11.6 KB
Accession
0001209191-22-056440
Insider Transaction Report
Form 4
Kelly Michael
Director
Transactions
- Award
Common Stock
2022-11-08+83,225→ 83,225 total(indirect: By Trust) - Award
Employee Stock Option (right to buy)
2022-11-08+70,422→ 70,422 totalExercise: $0.84Exp: 2029-07-04→ Common Stock (70,422 underlying) - Award
Employee Stock Option (Right to Buy)
2022-11-08+118,190→ 118,190 totalExercise: $1.44Exp: 2031-12-13→ Common Stock (118,190 underlying)
Footnotes (7)
- [F1]Received in exchange for 70,416 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.
- [F2]The Reporting Person's spouse and sister are trustees of the trust. The beneficiary of the trust is the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these Securities for purposes of Section 16 or for any other purpose.
- [F3]25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured the first anniversary of the vesting commencement date.
- [F4]Received in exchange for a stock option to acquire 59,584 shares of common stock of ARS pursuant to the Merger Agreement.
- [F5]Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.
- [F6]The shares vest in a series of thirty-six (36) successive equal monthly installments measured from the vesting commencement date.
- [F7]Received in exchange for a stock option to acquire 100,000 shares of common stock of ARS pursuant to the Merger Agreement.
Documents
Issuer
ARS Pharmaceuticals, Inc.
CIK 0001671858
Entity typeother
Related Parties
1- filerCIK 0001952533
Filing Metadata
- Form type
- 4
- Filed
- Nov 9, 7:00 PM ET
- Accepted
- Nov 10, 6:00 PM ET
- Size
- 11.6 KB